Stephanie L Nassar1, Heather M Conklin2, Yinmei Zhou3, Jason M Ashford2, Wilburn E Reddick4, John O Glass4, Fred H Laningham5, Sima Jeha6, Cheng Cheng3, Ching-Hon Pui6. 1. Mental Health and Behavioral Science Services, James A. Haley Veterans' Hospital, Tampa, Florida. 2. Department of Psychology, St. Jude Children's Research Hospital, Memphis, Tennessee. 3. Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee. 4. Division of Translational Imaging Research, St. Jude Children's Research Hospital, Memphis, Tennessee. 5. Department of Diagnostic Radiology, Children's Hospital Central California, Madera, California. 6. Departments of Oncology and Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee.
Abstract
BACKGROUND: Limited information is available regarding neurocognitive outcomes of children who experience seizures during treatment for acute lymphoblastic leukemia (ALL). Accordingly, the main objectives of this study were to determine the incidence and risk factors for treatment-related seizures among children with ALL, and the neurocognitive outcomes associated with treatment-related seizures. PROCEDURE: Prospective neuropsychological assessment and magnetic resonance imaging (MRI) were planned for all 498 patients with newly diagnosed ALL enrolled on the St. Jude Total Therapy XV (TOTXV) protocol at three time points. The study database was reviewed retrospectively to identify those with treatment-related seizure. To assess neurocognitive changes associated with seizure, each patient with treatment-related seizure was matched with two cohort patients without seizure for age at treatment, gender, race, and treatment intensity. RESULTS: Nineteen patients developed seizure, with a 2-year cumulative risk of 3.82 ± 0.86% (SE). No risk factors were identified to be associated with the development of seizure, with a possible exception of intensive chemotherapy used on the standard/high-risk arm as compared to the low-risk arm. Neuropsychological performance of the seizure group, as compared to normative scores and nonseizure control cohort, indicated problems in attention, working memory, and processing speed. Cognitive deficits persisted 2 years after therapy, with additional declines in intellectual function observed. MRI indicated early neurotoxicity among the seizure group, as evidenced by greater leukoencephalopathy on initial examinations. CONCLUSION: Treatment-related seizures were associated with leukoencephalopathy and decreased neuropsychological performance. Prospective studies are needed to detect changes in neurocognitive status associated with long-term functional impairment.
BACKGROUND: Limited information is available regarding neurocognitive outcomes of children who experience seizures during treatment for acute lymphoblastic leukemia (ALL). Accordingly, the main objectives of this study were to determine the incidence and risk factors for treatment-related seizures among children with ALL, and the neurocognitive outcomes associated with treatment-related seizures. PROCEDURE: Prospective neuropsychological assessment and magnetic resonance imaging (MRI) were planned for all 498 patients with newly diagnosed ALL enrolled on the St. Jude Total Therapy XV (TOTXV) protocol at three time points. The study database was reviewed retrospectively to identify those with treatment-related seizure. To assess neurocognitive changes associated with seizure, each patient with treatment-related seizure was matched with two cohort patients without seizure for age at treatment, gender, race, and treatment intensity. RESULTS: Nineteen patients developed seizure, with a 2-year cumulative risk of 3.82 ± 0.86% (SE). No risk factors were identified to be associated with the development of seizure, with a possible exception of intensive chemotherapy used on the standard/high-risk arm as compared to the low-risk arm. Neuropsychological performance of the seizure group, as compared to normative scores and nonseizure control cohort, indicated problems in attention, working memory, and processing speed. Cognitive deficits persisted 2 years after therapy, with additional declines in intellectual function observed. MRI indicated early neurotoxicity among the seizure group, as evidenced by greater leukoencephalopathy on initial examinations. CONCLUSION: Treatment-related seizures were associated with leukoencephalopathy and decreased neuropsychological performance. Prospective studies are needed to detect changes in neurocognitive status associated with long-term functional impairment.
Authors: Laura K Campbell; Mary Scaduto; William Sharp; Lynette Dufton; Deborah Van Slyke; James A Whitlock; Bruce Compas Journal: Pediatr Blood Cancer Date: 2007-07 Impact factor: 3.167
Authors: M N Dufourg; J Landman-Parker; M F Auclerc; C Schmitt; Y Perel; G Michel; P Levy; G Couillault; V Gandemer; M D Tabone; F Demeocq; J P Vannier; T Leblanc; G Leverger; A Baruchel Journal: Leukemia Date: 2006-12-14 Impact factor: 11.528
Authors: Wilburn E Reddick; John O Glass; Kathleen J Helton; James W Langston; Xiaoping Xiong; Shengjie Wu; Ching-Hon Pui Journal: AJNR Am J Neuroradiol Date: 2005-05 Impact factor: 3.825
Authors: Heather M Conklin; Raja B Khan; Wilburn E Reddick; Susan Helton; Ronald Brown; Scott C Howard; Melanie Bonner; Robbin Christensen; Shengjie Wu; Xiaoping Xiong; Raymond K Mulhern Journal: J Pediatr Psychol Date: 2007-06-14
Authors: Robert W Butler; Donna R Copeland; Diane L Fairclough; Raymond K Mulhern; Ernest R Katz; Anne E Kazak; Robert B Noll; Sunita K Patel; Olle Jane Z Sahler Journal: J Consult Clin Psychol Date: 2008-06
Authors: Ching-Hon Pui; Jun J Yang; Stephen P Hunger; Rob Pieters; Martin Schrappe; Andrea Biondi; Ajay Vora; André Baruchel; Lewis B Silverman; Kjeld Schmiegelow; Gabriele Escherich; Keizo Horibe; Yves C M Benoit; Shai Izraeli; Allen Eng Juh Yeoh; Der-Cherng Liang; James R Downing; William E Evans; Mary V Relling; Charles G Mullighan Journal: J Clin Oncol Date: 2015-08-24 Impact factor: 44.544
Authors: Nicholas S Phillips; Raja B Khan; Chenghong Li; Sedigheh Mirzaei Salehabadi; Tara M Brinkman; Deokumar Srivastava; Leslie L Robison; Melissa M Hudson; Kevin R Krull; Zsila S Sadighi Journal: Cancer Date: 2021-09-01 Impact factor: 6.860
Authors: Marita Partanen; Sean Phipps; Kathryn Russell; Doralina L Anghelescu; Joshua Wolf; Heather M Conklin; Kevin R Krull; Hiroto Inaba; Ching-Hon Pui; Lisa M Jacola Journal: J Pediatr Psychol Date: 2021-02-19